Antibody-drug conjugates (ADCs) continue to gain traction as a precision oncology modality, delivering cytotoxic agents directly to cancer cells and reducing systemic toxicities. Recent clinical approvals, ongoing trials of over 400 ADCs, and innovations in antibody targeting, linker chemistry, and payload development are expanding their application beyond hematologic malignancies to solid tumors and other diseases. Challenges remain in achieving safety and efficacy, but rising confidence among developers and clinicians is driving broader integration into cancer treatment paradigms.